CORPORATE OVERVIEW

JP Morgan Healthcare Conference 2023

COPYRIGHT © ABCELLERA

DISCLAIMER

This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

COPYRIGHT © ABCELLERA

AbCellera **is an antibody discovery engine** that delivers optimal clinical candidates to the clinic – and to patients – with **greater precision and speed.**



HYPOTHESIS

Investments in technology can **improve the productivity of drug development.**

PHILOSOPHY

Long-term value creation begins with building a great company that can **create multiple products.**

COPYRIGHT © ABCELLERA

DRUG DEVELOPMENT HAS THREE STEPS.

Target Identification

IDEATION

Drug Discovery

1000+ steps

regulations, technology, science, manufacturing, lab space, talent

PRODUCT CREATION

3 to 5 years

Clinical Development

PRODUCT TESTING

7 to 10 years

COPYRIGHT © ABCELLERA

TECHNOLOGY CAN MAKE A BIG IMPACT ON PRODUCT CREATION.

Illustrative drug development investment profile:



COPYRIGHT © ABCELLERA



STRATEGY #1

Be best in world in antibody therapeutics from **target to the clinic**.

STRATEGY #2

Build a **large and diversified portfolio of stakes** in future antibody therapeutics.

COPYRIGHT © ABCELLERA

STRATEGY #1

Be best in world in antibody therapeutics from **target to the clinic**.



- 2x faster
- solve the unsolvable
- highest quality
- unprecedented scale

COPYRIGHT © ABCELLERA

- **SPEED**

$100M+

NPV

by **accelerating approval** of an average antibody drug by 1 year

Billions

sales, profit, value

by being **first to market**

- **NEW MARKETS**

$100B+

new market opportunities

unlocked by **drugging the undruggable**

- **LEVEL THE PLAYING FIELD**

$50M+

small biotech savings

from not having to **reinvent the wheel**

Best-in-world capabilities create value.

COPYRIGHT © ABCELLERA

STRATEGY #2

Build a **large, diverse portfolio** of stakes in future antibody therapies.

PARTNER-INITIATED PROGRAMS

TECHNOLOGY-DEVELOPMENT

Discovery Programs



Co-Development Programs



Pre-Partnered Programs



COPYRIGHT © ABCELLERA

PARTNER-INITIATED PROGRAMS

Discovery Programs



TARGET

Partner-initiated

DEAL TERMS

- Upfronts and research fees
- Clinical milestones
- Single-digit royalties on net sales

High volume deals with highly diversified positions and high ROI.

COPYRIGHT © ABCELLERA

PARTNER-INITIATED PROGRAMS

Co-Development Programs



TARGET

Partner-initiated

DEAL TERMS

- Upfronts, clinical milestones, and royalty position
- PLUS option to co-invest in program development to maintain up to a 50% ownership position

Low volume deals with optionality for concentrated positions.

COPYRIGHT © ABCELLERA

TECHNOLOGY-DEVELOPMENT

Pre-Partnered Programs





T-Cell Engagers Platform

Untapped market opportunity in an area with a **high technical barrier** to entry and a rich target space that includes **many targets.**



GPCRs & Ion Channels Platform

High-value, **well-validated targets** that have been **intractable** using fragmented approaches and traditional technology.



Pandemic Response Platform

Tech-intensive challenge requiring **complex integration** to deliver antibody therapies quickly and bring **new treatments to** address emerging **variants.**

Technology development efforts with potential to generate first-in-class wholly-owned assets.

COPYRIGHT © ABCELLERA

PRE-PARTNERED PROGRAMS: PANDEMIC RESPONSE

FIRST PRE-PARTNERED PROGRAM IN COVID-19 RESULTED IN TREATMENTS FOR ~2.5M PATIENTS

Together with our partner, Lilly, AbCellera co-developed two antibody treatments authorized by the US FDA to treat COVID-19.



bamlanivimab

Nov 2020 – US FDA Authorization

bebtelovimab

Feb 2022 – US FDA Authorization

new candidate

Today – 3rd therapeutic antibody for COVID-19 in preclinical development

COPYRIGHT © ABCELLERA

PORTFOLIO DIVERSIFIED ACROSS MODALITIES, PARTNER SIZE, AND DEAL TYPE.

84
partner-initiated discovery programs

7
partner-initiated co-development programs

15
pre-partnered program targets initiated (GPCR, ion channels and TCE)

38
partners

7
molecules in the clinic

2
authorized antibody therapies



COPYRIGHT © ABCELLERA

10 YEARS BUILDING THE ENGINE.

capitalization

~$800M
in equity raised since 2012

$150M+
in government contracts and financing

30% +
held by employees & directors

investments

~500
employees across 4 countries and 3 continents

640K+
sq.ft. of facilities
lab, office, & manufacturing spaces by 2024

$500M+
platform investments

financials

~$860M
in cash, cash equivalents & marketable securities

$450M
in accumulated earnings since 2012

COPYRIGHT © ABCELLERA

2/3 TECHNOLOGY & COMPANY BUILDING

PRE-PARTNERED PROGRAMS

- GPCRs and ion channels
- T-cell engagers
- Pandemic response (COVID-19)

PEOPLE & PLATFORM

- Team development
- Data science
- Translational science
- Manufacturing

1/3 PARTNERING

PARTNERED PROGRAMS

- Deal quality, not volume
- Deeper partnerships that get partners to the clinic
- Execute on and expand existing partnerships



AbCellera's capital allocation

COPYRIGHT © ABCELLERA

IT'S BECAUSE IT'S HARD THAT IT'S VALUABLE & IT'S DEFENSIBLE.



AbCellera's competitive moat

COPYRIGHT © ABCELLERA

This is what's needed to **solve the problem.**

FROM **TARGET**

TO **DRUG**



COPYRIGHT © ABCELLERA

THANK YOU



COPYRIGHT © ABCELLERA